Page 182 - CW E-Magazine (21-11-2023)

Document

commitment to accessible, high- way for more substantial investments Indian pharma and medical device
quality healthcare for all. in the sector. products and companies: Collabo-
Collaboration at inter-ministerial rating with international partners to
level (DoHFW, AYUSH, ICMR, International collaborations will promote and expand the reach of
DBT) and at inter-departmental level boost the global standing of India’s Indian pharma and medical device
to integrate pharma policies and pharma sectors by addressing chal- products and companies world-
objectives with broader healthcare lenges, attracting investments, foster- wide with assistance from Pharm-
initiatives, enhancing the overall ing innovation, and promoting regula- excil by driving initiatives such as
health system’s efficiency and tory harmonisation. Bringing together joint marketing efforts, and partner-
effectiveness. various stakeholders and facilitating ships with global distributors and
Through these strategic interlink- communication and cooperation with healthcare providers.
ages, the policy leverages the foreign governments, organisations, and Facilitate acceptance of Indian

strengths and resources of multiple industry players is crucial to achieving standards: Advocating for the rec-
stakeholders, including government these objectives and ensuring the ognition and adoption of Indian
agencies, industry players, research continued growth and competitiveness pharmacopeia standards in global
institutions, and civil society. It on a global scale. pharma regulations, facilitating
creates a harmonious convergence smoother international trade and
of efforts that not only accelerates Access to markets: Facilitating harmonisation of quality standards.

the achievement of pharma policy market access for Indian pharma Enhance global collaborations for

objectives, but also contributes to companies in foreign countries by API manufacturing: APIs are essen-
the overall advancement of India’s addressing trade barriers, tariffs, tial components of pharma pro-
healthcare landscape. and regulatory hurdles. ducts. Collaboration on sourcing
Facilitating the identification of Supply chain integration: Coordi- raw materials, sharing technology,

synergistic opportunities between nating with international partners and establishing joint ventures to
different sectors and leveraging the to create more efficient and resi- manufacture APIs, ensuring a stable
strengths of different policies and lient pharma supply chains which and cost-effective supply chain.
resources to maximise the impact caters to both domestic and global Forging international partnerships

on pharma ecosystem will chan- demands. for decentralised manufacturing faci-
nelise resources, investments, and International R&D collaboration: lities and government-to-govern-

support to areas that have the most Collaborating with international re- ment drug distribution initiatives.
potential for success. search institutions and laboratories, Promote Indian pharma exports by

with the institutes like NIPERs, to upholding high-quality manufactur-
NPP 2023 recognises that its true foster innovation and research in ing standards and compliance with
potential lies not in isolation, but in its new and emerging areas of health- international regulatory require-
ability to weave a tapestry of collabo- care. This may include joint re- ments, strengthening India’s posi-
ration and synergy, creating a stronger, search projects, capacity building, tion as a global pharma hub and
more resilient healthcare system that skilling, and training in compliance harmonisation with international
serves the diverse healthcare needs of with international quality standards standards.
the nation. and regulations among others.
Health diplomacy: Collaborating with Infrastructure enhancement and
International collaboration foreign governments and organisa- strengthening logistics
Given India’s extensive dealings tions on global health initiatives, such An efficient logistics ecosystem is an
with numerous countries, it is crucial as vaccine distribution, disease con- important requirement for the pharma
to study and comprehend the problems trol, and pandemic response. industry ensuring the stability and
encountered by the sector. Understand- Trade agreements: Negotiating trade durability of medicines throughout
ing international needs and areas of agreements and partnerships for the value chain. Improvements in the
cooperation can build trust and confidence advanced technology transfer, IPR logistics infrastructure can help pharma
in Indian pharma products. Further, it protection, expanding local manu- industry to service patients better and
can significantly increase acceptance facturing plants, and international also build competitive advantage. The
and create channels to assess country- clinical trials, among others. key issue faced by the pharma industry
specific needs, ultimately paving the Bolster the global presence of in India is relatively higher logistics

182 Chemical Weekly November 21, 2023

Contents Index to Advertisers Index to Products Advertised